Craig's Cause Pancreatic Cancer Society and The Canadian Association of General Surgeons is pleased to announce the 2023 National Pancreas Conference.

Included in the cost of registration;

The National Pancreas Conference will be offered as a hybrid conference, both in-person and virtual.

Venue Information: 
The conference is taking place at the Best Western Ville-Marie
3407 Rue Peel, Montréal
Québec H3A 1W7

More information included in ticket email.

Award Information and Criteria:

Important Dates for ALL Awards: 

NPC 2023 Presenters:

Dr. Keith Roberts

HPB Surgeon

Prof Keith Roberts is a HPB and liver transplant surgeon at University Hospitals Birmingham NHS Trust and Honorary Professor at the University of Birmingham. He is the pancreas cancer subspeciality lead for the Royal College of Surgeons of England and Honorary Treasurer to the Pancreatic Society of Great Britain and Ireland. His research expertise is in pancreatic exocrine insufficiency, post operative pancreatic fistula and pathways to surgery for pancreatic cancer.

Dr. Keith Roberts

Keynote Speaker: PERT and Improving Patient Outcomes

Dr. Erica Tsang

GI Medical Oncologist

Dr. Erica Tsang is a GI medical oncologist at the Princess Margaret Cancer Centre and an Assistant Professor at the University of Toronto. She completed her Internal Medicine and Medical Oncology training at the University of British Columbia, followed by further training in GI and early phase oncology at the University of California San Francisco. She also completed a Masters of Public Health at Harvard University. Her research interests involve genomics and clinical trials, with a focus on pancreatic cancer.

Dr. Erica Tsang

Panelist: Clinical Trials

Valerie Cooper

Nurse Practitioner in Hospice and Palliative Care

Valerie Cooper is a Hospice Palliative Care Nurse Practitioner with Home and Community Care Support Services South East. She sees patients in their homes in a variety of geographies, from urban to remote. She works in a shared-care model with patients’ existing primary care providers to support patients with malignancies and end-stage organ diseases to die in their preferred place of death. She lectures in the undergraduate program at Queen’s School of Nursing and has developed and taught an elective undergraduate course on hospice palliative care nursing. She has also contributed to a continuing education course for nurse practitioners on palliative care through the University of Toronto. Valerie is a member of the Dying with Dignity Canada’s Clinician Advisory Council, the Canadian Association of MAiD Assessors and Providers (CAMAP) Provincial and Territorial Advisory Council, as well as the CAMAP National MAiD Curriculum Working Group. She is the chair of her local MAiD Community of Practice, as well as a LEAP facilitator for Pallium Canada. She has spoke across Canada about both palliative care and MAiD

Valerie Cooper

Panelist: Palliative Care and Mental Health

Dr. Breffni Hannon

Clinician Investigator/Palliative Care Physician

Dr. Breffni Hannon leads the palliative care program at the Princess Margaret Cancer Centre in Toronto. Originally from Ireland, she moved to Canada for a 2-year clinical-research fellowship in palliative care in 2011 and never left! She is a clinician-investigator whose research interests include developing models of early palliative care for patients with advance cancer; exploring the needs of caregivers; and promoting advance care planning.

Dr. Breffni Hannon

Panelist: Palliative Care and Mental Health

Dr. George Zogopolous

HPB Surgeon

George Zogopoulos, MD, PhD, FRCS(C), FACS is an Associate Professor of Surgery and Oncology at McGill University and a hepato-pancreato-biliary and transplant surgeon at the MUHC. He completed his clinical training at the University of Toronto, where he obtained his medical degree, followed by residency in general surgery and surgical fellowship in hepato-pancreato-biliary surgical oncology and abdominal organ transplant surgery. His research training was completed at McGill University and at the University of Toronto. He obtained his Ph.D. in Experimental Medicine at McGill University, studying the regulatory mechanisms of a gene responsible for human growth. He is a junior 2 clinical research scholar of the Fonds de recherche du Quebec and a scientist at the Research Institute of the MUHC and the GCRC. His research program is centered on the genetics and oncogenomics of pancreatic cancer, and his clinical practice is built around and driven by his research focus.

Dr. George Zogopolous

Panelist: Diagnosis and Screening

Dr. Sharlene Gill

Medical Oncologist

Dr. Sharlene Gill is a medical oncologist specializing in gastrointestinal (GI) malignancies at BC Cancer – Vancouver. She received a BSc. in Pharmacy, and MD from the University of British Columbia in 1996 followed by residencies in Internal Medicine and Medical Oncology, subsequently completing a fellowship in Gl Oncology at the Mayo Clinic (Rochester, MN) and a Masters of Public Health from the Harvard School of Public Health (Boston, MA) before returning to Vancouver where she is presently Professor of Medicine at the University of British Columbia. In 2017, she completed an MBA from the Kenan-Flagler School of Business at the University of North Carolina. Her areas of clinical expertise are in colorectal, pancreatic and hepatobiliary cancers. She is actively engaged in education and clinical research, with over 100 peer-reviewed publications and book chapters to her credit.

Dr. Sharlene Gill

Panelist: Clinical Trials

Dr. Brent Johnston

Scientist (Microbiology and Immunology)

Dr. Brent Johnston is Professor and Head of the Department of Microbiology & Immunology at Dalhousie University and a Senior Scientist with the Beatrice Hunter Cancer Research Institute. He obtained his PhD from the University of Calgary and completed a postdoctoral fellowship at Stanford University. Dr. Johnston’s research program uses models of cancer and autoimmune disease to understand the role of natural killer T (NKT) cells in regulating immune responses and disease outcomes. Dr. Johnston’s group is currently working to develop cancer therapies that incorporate NKT cell-based immunotherapy in combination with select chemotherapeutics, oncolytic viruses, and immune checkpoint antibodies.

Dr. Brent Johnston

Panelist: Treatment

Filomena Servidio-Italiano

President - CCRAN

Filomena is the President and CEO of the Colorectal Cancer Resource & Action Network (“CCRAN”) – a patient-focused organization championing the health and wellbeing of Canadians touched by colorectal cancer and others at risk of developing the disease. Her undergraduate and graduate work lie in the biological sciences and educational studies. As a caregiver to her father, who was afflicted with and succumbed to metastatic cancer, his journey has served as the impetus for the founding of CCRAN, one month post his passing in August of 2006. The past seventeen years have been dedicated to the cause of supporting, educating, and advocating on behalf of colorectal cancer patients and caregivers, to improve patients’ quality of life and longevity through the provision of evidence-based information and access to innovative patient programs, such as CCRAN’s innovative “My CRC Consultant”, an online tool providing the metastatic patient with evidence-based and expert reviewed, potential therapeutic options based on the patient’s tumour’s molecular profile. She has been working closely with valued health care professionals across the continuum of colorectal cancer care to ensure content acumen. She is humbled to be published alongside world-renowned experts in areas such as colorectal cancer management, PROs and PROMs, early age onset colorectal cancer awareness and education, promoting national LDLT efforts, education on molecular profiling, and more.

Filomena is a strong proponent of HTA patient evidence submissions since the inception of pCODR, ensuring the patient voice is captured and well incorporated into her submissions. She prepares these submissions not only for colorectal cancer drug therapies under review, but within therapeutic areas for which there are no representative patient advocacy groups or on behalf of patient advocacy groups who may not have the capacity to make these critically important submissions. She strives to secure robust patient and caregiver participation to help identify patients’ unmet needs, as well as capture their fundamentally important values, preferences, and priorities with the goal of ultimately ensuring reimbursement of effective treatments based on thoughtful and compelling input. She continues to be a passionate advocate for the Canadian cancer patient and their caregiver.

Filomena Servidio-Italiano

Panelist: Multidisciplinary Care Model

Dr. Ravi Ramjeesingh

Medical Oncologist

Dr. Ramjeesingh holds an MD and PhD from the University of Toronto and completed residency training in internal medicine and medical oncology through Queen’s University. He then undertook a two-year clinical trial methodology and translational research fellowship with the NCIC Clinical Trials Group at Queen’s. His work focused on the appropriate timing of administration of adjuvant chemotherapy to patients with breast cancer.

Dr. Ravi Ramjeesingh

Panelist: Clinical Trials

Our Scientific Committee:

Michael Moser

MD, MSc, FRCSC

Saskatchewan

Dr. Mike Moser completed medical school and surgical residency at the University of Alberta in Canada, then completed a fellowship under the mentorship of Dr. William Wall in London, Ontario in Hepatobiliary Surgery and Transplantation.

Dr. Moser currently practices in Saskatoon, at the University of Saskatchewan as a hepatobiliary and transplant surgeon and maintains a keen interest in tumor ablation and surgical education. Dr. Moser is involved in collaborative research with the Departments of Biomedical Engineering, Chemistry, Oncology, Pharmacology, and Immunology, studying ways of improving the effectiveness of the NanoKnife, while maintaining the relative safety of this novel ablation technology.

Michael Moser

MD, MSc, FRCSC

Saskatchewan

Sharlene Gill

MD, MPH, MBA, FACP, FRCP(C)

British Columbia

Dr. Sharlene Gill is a medical oncologist specializing in gastrointestinal (GI) malignancies at BC Cancer – Vancouver.  She received a BSc. in Pharmacy, and MD from the University of British Columbia in 1996 followed by residencies in Internal Medicine and Medical Oncology, subsequently completing a fellowship in Gl Oncology at the Mayo Clinic (Rochester, MN) and a Masters of Public Health from the Harvard School of Public Health (Boston, MA) before returning to Vancouver where she is presently Professor of Medicine at the University of British Columbia.  In 2017, she completed an MBA from the Kenan-Flagler School of Business at the University of North Carolina.  Her areas of clinical expertise are in colorectal, pancreatic and hepatobiliary cancers.  She is actively engaged in education and clinical research, with over 100 peer-reviewed publications and book chapters to her credit.

Sharlene Gill

MD, MPH, MBA, FACP, FRCP(C)

British Columbia

Julie Hallet

MD, MSc, FRCSC

Ontario

Dr. Hallet is an Assistant Professor of Surgery at the University of Toronto and a Surgical Oncologist at the Odette Cancer Centre - Sunnybrook Health Sciences Centre specialized in hepato-biliary, pancreatic and upper gastrointestinal malignancies, with a clinical focus on minimally invasive and image-guided therapies, as well as neuroendocrine tumours as part of the Susan Leslie Multidisciplinary Clinic for Neuroendocrine Tumors. She completed her general surgery residency and MSc in Clinical Epidemiology at Université Laval in Québec City, followed by a Surgical Oncology fellowship in the hepato-pancreatio-biliary track program at the University of Toronto, and additional training in advanced minimally invasive and robotic hepato-pancreatico-biliary surgery at the Institut de recherche contre les cancers de l’appareil digestif (IRCAD) in Strasbourg, France.

As a surgeon investigator, Dr. Hallet’s research focuses on health services research to examine processes, patterns of care, and outcomes of hepato-pancreato-biliary malignancies, with a focus on patient engagement and patient-reported/patient-centred outcomes. In particular, her research is supported by operating grants from the Canadian Institutes of Health Research and the Ontario Institute of Cancer Research, as well as prior early career investigator awards from the Society of Surgery of the Alimentary Tract and the North-American Neuroendocrine Tumors Society.

Julie Hallet

MD, MSc, FRCSC

Ontario

Rob Grant

PhD

Ontario

Dr. Robert Grant is a medical oncologist at Princess Margaret Cancer Centre who treats patients with pancreatic cancer. His research focuses on using machine learning to improve outcomes in oncology.

Rob Grant

PhD

Ontario

Popi Kasvis

PhD, RD

Québec

Popi Kasvis is a Clinical Nutritionist/Dietitian at the McGill University Health Centre in Montreal, working within the multidisciplinary Cancer Rehabilitation Program (CAREPRO). Briefly, her clinical duties include:

1) assessing patients for the presence of malnutrition/sarcopenia/cachexia.

2) creating a nutritional treatment plan to optimize nutritional status.

3) managing nutrition impact symptoms.

Any patient with cancer, including pancreatic cancer, at any stage of disease and into survivorship, may be referred to CAREPRO. Popi received a PhD in the department of Health and Exercise Science at Concordia University. Her research is focused on the effect of early diet and exercise interventions on the health-related quality of life of patients with pancreatic cancer, undergoing both curative and palliative treatments.

Popi Kasvis

PhD, RD

Québec

Ravi Ramjeesingh

MD, PhD

Nova Scotia

Dr. Ramjeesingh holds an MD and PhD from the University of Toronto and completed residency training in internal medicine and medical oncology through Queen’s University. He then undertook a two-year clinical trial methodology and translational research fellowship with the NCIC Clinical Trials Group at Queen’s. His work focused on the appropriate timing of administration of adjuvant chemotherapy to patients with breast cancer.

Ravi Ramjeesingh

MD, PhD

Nova Scotia

Mark Walsh

MD, MSc, FRCSC

Nova Scotia

Dr. Mark Walsh MD MSc FRCSC is a Hepato-Pancreatico-Biliary surgeon at the QEII Health Sciences Centre and an Assistant Professor and Director of Quality Improvement at Dalhousie University, in Nova Scotia Canada.

Mark Walsh

MD, MSc, FRCSC

Nova Scotia

Jeanette Boudreau

BSc, PhD

Nova Scotia

Dr. Jeanette Boudreau received her PhD from McMaster University and completed post-doctoral training at Memorial Sloan Kettering Cancer Center. Dr. Boudreau’s laboratory focuses on human natural killer cells as indicators and tools for cancer immunotherapy. Her group is interested in both the genetic and functional aspects of pancreatic cancer and the immune system, and how they factor into development and treatment of cancer. The Boudreau laboratory uses high-parameter flow cytometry, microscopy and humanized animal models to study immune-tumor interactions.

Jeanette Boudreau

BSc, PhD

Nova Scotia

Mustapha Tehfe

MD, MSc

Québec

Mustapha Tehfe is a professor in the Department of Medicine at the University of Montreal and hemato-oncologist at the Center hospitalier de l'Université de Montréal (CHUM).

Mustapha Tehfe

MD, MSc

Québec

George Zogopoulos

MD, PhD, FRCS(C), FACS

Québec

George Zogopoulos, MD, PhD, FRCS(C), FACS is an Associate Professor of Surgery and Oncology at McGill University and a hepato-pancreato-biliary and transplant surgeon at the MUHC. He completed his clinical training at the University of Toronto, where he obtained his medical degree, followed by residency in general surgery and surgical fellowship in hepato-pancreato-biliary surgical oncology and abdominal organ transplant surgery. His research training was completed at McGill University and at the University of Toronto. He obtained his Ph.D. in Experimental Medicine at McGill University, studying the regulatory mechanisms of a gene responsible for human growth. He is a junior 2 clinical research scholar of the Fonds de recherche du Quebec and a scientist at the Research Institute of the MUHC and the GCRC. His research program is centered on the genetics and oncogenomics of pancreatic cancer, and his clinical practice is built around and driven by his research focus.

George Zogopoulos

MD, PhD, FRCS(C), FACS

Québec

Developed by:

Craig's Cause Pancreatic Cancer Society LogoCanadian Association of General Surgeons Logo